Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Integrum AB (publ) (INTEG-B.ST)
Mölndal, SE
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-anchored prosthesis integrates directly with the patient's bone through osseointegration, thus circumventing the need for a conventional socket. A significant benefit of the OPRA system is its protective quality, helping to prevent bone fractures from accidental loads. Additionally, Integrum provides Neuromotus, a therapeutic technology designed to mitigate phantom limb pain following an amputation. These sophisticated implant systems are distributed worldwide to hospitals, clinics, and orthopedic professionals. The company was founded in 1962 and is based in Mölndal, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.50% | +0.75% | +9.08% | +3.21% | -25.60% | -22.60% | -59.85% | -64.30% | -86.45% | -60.34% | -60.34% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+0.3% Q2'26: -7.7% (vs Q2'25)
-
EPS growth Medical - Devices: +28.5%-36.6% Q2'26: -57.1% (vs Q2'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+2.2% Q2'26: +0.0% (vs Q2'25)
-
EBIT margin Medical - Devices: +6.2%-56.4% Q2'26: -80.1% (vs Q2'25)
-
ROIC Medical - Devices: +3.3%-33.0% Q2'26: -44.1% (vs Q2'25)
-
Share dilution Medical - Devices: 0.0%+9.8% Q2'26: +25.0% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.08× Q2'26: -0.06× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Apr 2021 actual |
Apr 2022 actual |
Apr 2023 actual |
Apr 2024 actual |
Apr 2025 actual |
Apr 2026 1 Rev. Ana. 1 EPS Ana. |
Apr 2027 1 Rev. Ana. 1 EPS Ana. |
Apr 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
43.09M
est: 73.00M (-41.0%)
|
55.72M
est: 80.00M (-30.3%)
|
74.27M
est: 77.50M (-4.2%)
|
104.12M
est: 109.51M (-4.9%)
|
91.10M
est: 90.50M (+0.7%)
|
133.00M
133.00M – 133.00M
+47.0% YoY
|
209.00M
209.00M – 209.00M
+57.1% YoY
|
261.00M
261.00M – 261.00M
+24.9% YoY
|
| EBITDA |
-1.59M
est: -8.29M (+80.9%)
|
2.60M
est: -9.09M (+128.6%)
|
-20.24M
est: -8.81M (-129.8%)
|
8.76M
est: -21.13M (+141.5%)
|
-35.50M
est: -17.47M (-103.2%)
|
-25.67M
-25.67M – -25.67M
-47.0% YoY
|
-40.33M
-40.33M – -40.33M
-57.1% YoY
|
-50.37M
-50.37M – -50.37M
-24.9% YoY
|
| EBIT |
-2.09M
est: -10.38M (+79.8%)
|
1.34M
est: -11.37M (+111.7%)
|
-21.40M
est: -11.02M (-94.2%)
|
6.60M
est: -26.85M (+124.6%)
|
-42.04M
est: -22.19M (-89.4%)
|
-32.61M
-32.61M – -32.61M
-47.0% YoY
|
-51.24M
-51.24M – -51.24M
-57.1% YoY
|
-63.99M
-63.99M – -63.99M
-24.9% YoY
|
| Net Income |
-2.14M
est: -17.07M (+87.5%)
|
21.27M
est: -6.32M (+436.6%)
|
-16.18M
|
4.03M
est: -2.99M (+235.0%)
|
-30.85M
est: -32.38M (+4.7%)
|
-2.78M
-2.78M – -2.78M
+91.4% YoY
|
15.96M
15.96M – 15.96M
+675.0% YoY
|
28.22M
28.22M – 28.22M
+76.8% YoY
|
| SGA |
18.90M
est: 30.86M (-38.8%)
|
29.58M
est: 33.82M (-12.5%)
|
84.97M
est: 32.76M (+159.4%)
|
—
est: 36.68M (-100.0%)
|
—
est: 30.32M (-100.0%)
|
44.55M
44.55M – 44.55M
+47.0% YoY
|
70.01M
70.01M – 70.01M
+57.1% YoY
|
87.43M
87.43M – 87.43M
+24.9% YoY
|
| EPS |
-0.14
est: -0.80 (+82.5%)
|
1.20
est: -0.30 (+505.1%)
|
-0.88
|
0.23
est: -0.13 (+280.4%)
|
-1.45
est: -1.38 (-4.9%)
|
-0.12
-0.12 – -0.12
+91.4% YoY
|
0.68
0.68 – 0.68
+675.0% YoY
|
1.20
1.20 – 1.20
+76.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-03 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-02 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-01 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rickard Branemark | Founder, Owner, Chief Medical & Scientific Officer and Chairman of the Board | 7M | — |
| Anna-Tove Branemark | Chief Executive Officer of Integrum Inc. | — | female |
| Annika Fahlén | Chief Compliance & Development Officer | — | — |
| Louise Wahlin | Chief Financial Officer | — | female |
| Martin Hillsten | Chief Executive Officer | — | male |
| Per Nilsson | Chief Supply & IT Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INTEG-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
